Jun Cheon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jun Cheon has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
H.S. Park
5 shared publicationsJ.J. Kim
5 shared publications- Akinobu Gotoh
Department of Urology, Kobe University School of Medicine, Kobe, Japan
4 shared publications C Kao
4 shared publicationsJ.G. Lee
4 shared publicationsL W Chung
4 shared publications
Latest Publications
- 1 April 2018
- Published by Elsevier in European Journal of Cancer
- Vol. 92, S35
Assessment of quality of breast cancer survivorship using wireless touch screen tablet personalized computer
- 1 April 2018
- Published by Elsevier in European Journal of Cancer
- Vol. 92, S35
Assessment of quality of breast cancer survivorship using wireless touch screen tablet personalized computer
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S404
P585 Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015
The optimal timing of thiopurine (azathioprine or 6-mercaptopurine) administration is controversial issue in treatment of Crohn's disease (CD) with poor prognostic factors. We performed a nationwide population-based study to investigate the impact of timing of thiopurine treatment on first intestinal resection in CD with poor prognostic factors. Using the National Health Insurance claims data, we collected data on newly diagnosed patients with CD between 2004 and 2015. Among them, patient who have at least two risk factors for progression (diagnosis at age p = 0.225), meanwhile, the risk of surgery was significantly increased in patients started thiopurine at 12–24 months after diagnosis (hazard ratio 1.62, 95% confidence interval 1.10–2.40, p = 0.015). Compared with patients received thiopurine within 6 months, 62% of increase for surgery risk was observed in patients started thiopurine at 12–24 months. Our results suggest that initiation of thiopurine within 1 year after diagnosis may be considered in CD patients with poor prognostic factors.
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S404
P585 Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015
The optimal timing of thiopurine (azathioprine or 6-mercaptopurine) administration is controversial issue in treatment of Crohn's disease (CD) with poor prognostic factors. We performed a nationwide population-based study to investigate the impact of timing of thiopurine treatment on first intestinal resection in CD with poor prognostic factors. Using the National Health Insurance claims data, we collected data on newly diagnosed patients with CD between 2004 and 2015. Among them, patient who have at least two risk factors for progression (diagnosis at age p = 0.225), meanwhile, the risk of surgery was significantly increased in patients started thiopurine at 12–24 months after diagnosis (hazard ratio 1.62, 95% confidence interval 1.10–2.40, p = 0.015). Compared with patients received thiopurine within 6 months, 62% of increase for surgery risk was observed in patients started thiopurine at 12–24 months. Our results suggest that initiation of thiopurine within 1 year after diagnosis may be considered in CD patients with poor prognostic factors.
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S517
P801 Trends in inflammatory bowel disease incidence in Korea: A nationwide population-based study 2004–2015
Although the incidence of inflammatory bowel disease (IBD) has been known to increase in Asian countries, the detailed epidemiologic features are not well known. We extracted all claim data of IBD patients in National Health Insurance Database (NHID) from 2002 to 2015, which was defined as those who had main diagnostic code of Crohn’s disease (CD) [K50] or Ulcerative colitis (UC) [K51] and have been prescribed relevant drugs simultaneously. We excluded patients who were diagnosed as IBD patients between 2002 and 2003 to select incident cases only. Annual age-standardised incidence rate was calculated, and Joinpoint regression was used for statistical analysis to compute annual percent changes (APC) in incidence rates. A total of 55613 IBD patients (17178 for CD and 38435 for UC) were identified from 2004 to 2015. The age-specific incidence rate of CD peaked at 10–29 years old in both men (9.04/100000) and women (3.37/100000) between 2004 and 2015. The incidence rate of CD was significantly increased in men aged 10–19 (APC = 12.2%), 20–29 (5.8%), and 30–39 (2.3%) and women aged 10–19 (11.4%), and 20–29 (3.0%), whereas significant decreases were observed for men aged 50–59 (−2.5%), and 80+ years (−9.8%) and women aged 40–49 (−4.9%), 50–59 (−4.0%), and 60–69 years (−4.9%). Meanwhile, the age-specific incidence rate of UC peaked in 60–69 years old in both men (12.87/100000) and women (9.86/100000) between 2004 and 2015. Significant increase in incidence rates of UC was observed in men aged 10–19 (6.8%), 20–29 (5.5%), and 30–39 (2.0%), and women aged 10–19 (9.7%), and 20–29 (3.7%), whereas significant decrease was observed for men aged 80+ years (−4.8%) and women aged 40–49 (−2.2%), 50–59 (−3.1%), 60–69 (−4.6%), and 70–79 (−4.8%) years old. The incidence rate of CD was 3.29/100000 in metropolitan area and 2.96/100000 in non-metropolitan area, which were both annually increasing (APC of CD in metropolitan area: 4.7%, non-metropolitan area: 4.0%). Meanwhile, the incidence rate of UC was 7.15/100000 in metropolitan area and 7.02/100000 person-years in non-metropolitan area, which were increasing in both areas (APC of UC in metropolitan area: 1.6%, non-metropolitan area: 1.1%). The incidence of both CD and UC in Korea was increased between 2004 and 2015. Metropolitan area showed higher incidence rate than non-metropolitan area. The most prominent increase of CD incidence was observed in 10–39 years old men and 10–29 years old women during the study period.
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S517
P801 Trends in inflammatory bowel disease incidence in Korea: A nationwide population-based study 2004–2015
Although the incidence of inflammatory bowel disease (IBD) has been known to increase in Asian countries, the detailed epidemiologic features are not well known. We extracted all claim data of IBD patients in National Health Insurance Database (NHID) from 2002 to 2015, which was defined as those who had main diagnostic code of Crohn’s disease (CD) [K50] or Ulcerative colitis (UC) [K51] and have been prescribed relevant drugs simultaneously. We excluded patients who were diagnosed as IBD patients between 2002 and 2003 to select incident cases only. Annual age-standardised incidence rate was calculated, and Joinpoint regression was used for statistical analysis to compute annual percent changes (APC) in incidence rates. A total of 55613 IBD patients (17178 for CD and 38435 for UC) were identified from 2004 to 2015. The age-specific incidence rate of CD peaked at 10–29 years old in both men (9.04/100000) and women (3.37/100000) between 2004 and 2015. The incidence rate of CD was significantly increased in men aged 10–19 (APC = 12.2%), 20–29 (5.8%), and 30–39 (2.3%) and women aged 10–19 (11.4%), and 20–29 (3.0%), whereas significant decreases were observed for men aged 50–59 (−2.5%), and 80+ years (−9.8%) and women aged 40–49 (−4.9%), 50–59 (−4.0%), and 60–69 years (−4.9%). Meanwhile, the age-specific incidence rate of UC peaked in 60–69 years old in both men (12.87/100000) and women (9.86/100000) between 2004 and 2015. Significant increase in incidence rates of UC was observed in men aged 10–19 (6.8%), 20–29 (5.5%), and 30–39 (2.0%), and women aged 10–19 (9.7%), and 20–29 (3.7%), whereas significant decrease was observed for men aged 80+ years (−4.8%) and women aged 40–49 (−2.2%), 50–59 (−3.1%), 60–69 (−4.6%), and 70–79 (−4.8%) years old. The incidence rate of CD was 3.29/100000 in metropolitan area and 2.96/100000 in non-metropolitan area, which were both annually increasing (APC of CD in metropolitan area: 4.7%, non-metropolitan area: 4.0%). Meanwhile, the incidence rate of UC was 7.15/100000 in metropolitan area and 7.02/100000 person-years in non-metropolitan area, which were increasing in both areas (APC of UC in metropolitan area: 1.6%, non-metropolitan area: 1.1%). The incidence of both CD and UC in Korea was increased between 2004 and 2015. Metropolitan area showed higher incidence rate than non-metropolitan area. The most prominent increase of CD incidence was observed in 10–39 years old men and 10–29 years old women during the study period.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi187
BRAF mutated metastatic colorectal cancers do not always possess poor clinical outcome
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi187
BRAF mutated metastatic colorectal cancers do not always possess poor clinical outcome
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e931
931 Synergistic antitumor effect of satraplatin and NVP-BEZ235 in cisplatin-resistant human bladder cancer cells
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e931
931 Synergistic antitumor effect of satraplatin and NVP-BEZ235 in cisplatin-resistant human bladder cancer cells
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e462
462 Computed tomography-based novel prediction model for the outcome of SWL in proximal ureteral stone
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e462
462 Computed tomography-based novel prediction model for the outcome of SWL in proximal ureteral stone
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part5) , 134-135
SU‐E‐I‐43: Automatic Exposure Control Or Fixed Tube Current? : Evaluating Dose Effectiveness of AEC in Pediatric Chest CT Examinations with CTDIvol, SSDE, and Water‐Equivalent SSDE
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part5) , 134-135
SU‐E‐I‐43: Automatic Exposure Control Or Fixed Tube Current? : Evaluating Dose Effectiveness of AEC in Pediatric Chest CT Examinations with CTDIvol, SSDE, and Water‐Equivalent SSDE
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e66-e66a
66 Short-phase training on a robotic virtual reality simulator (Mimic dV Trainer™)
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e66-e66a
66 Short-phase training on a robotic virtual reality simulator (Mimic dV Trainer™)